Incidence of bleeding after 15,181 percutaneous biopsies and the role of aspirin

Thomas D. Atwell, Ryan L. Smith, Gina K. Hesley, Matthew R Callstrom, Cathy D. Schleck, W. Scott Harmsen, J. William Charboneau, Timothy J. Welch

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

OBJECTIVE. The objective of our study was to report the incidence of bleeding after imaging-guided percutaneous core biopsy at a single center using a standardized technique. MATERIALS AND METHODS. We performed a retrospective review of percutaneous core biopsies performed at our institution from January 2002 through February 2008. Data were collected at the time of biopsy, and clinical information was obtained 24 hours and 3 months after the biopsy. The specific information that was collected included the results of coagulation studies, aspirin use, the organ biopsied, the size of the biopsy needle, and the number of needle passes. Bleeding complications were defined using the Common Terminology Criteria for Adverse Events (CTCAE, version 3.0) established by the National Cancer Institute. RESULTS. Among the 15,181 percutaneous core biopsies performed during the study period, 70 hemorrhages (0.5%) that were CTCAE grade 3 or greater were identified within 3 months of biopsy. The incidence of bleeding in patients taking aspirin within 10 days before biopsy was 0.6% (18/3,195), which was not statistically different compared with the incidence of bleeding in those not taking aspirin (52/11,986, 0.4%; p = 0.34). The incidence of bleeding after liver biopsy was 0.5%; kidney biopsy, 0.7%; lung biopsy, 0.2%; pancreas biopsy, 1.0%; and other biopsy, 0.2%. There were significant associations between major bleeding and serum platelet count and international normalized ratio (p <0.001), although the association between major bleeding and the size of the biopsy needle was not significant (p = 0.97). CONCLUSION. The overall incidence of major bleeding after imaging-guided percutaneous core needle biopsy is low. Recent aspirin therapy does not appear to significantly increase the risk of such bleeding complications.

Original languageEnglish (US)
Pages (from-to)784-789
Number of pages6
JournalAmerican Journal of Roentgenology
Volume194
Issue number3
DOIs
StatePublished - Mar 2010

Fingerprint

Aspirin
Hemorrhage
Biopsy
Incidence
Needle Biopsy
Large-Core Needle Biopsy
International Normalized Ratio
Organ Size
National Cancer Institute (U.S.)
Platelet Count
Terminology
Needles
Pancreas
Kidney
Lung
Liver

Keywords

  • Aspirin
  • Biopsy
  • Complications
  • Hemorrhage
  • Percutaneous biopsy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Atwell, T. D., Smith, R. L., Hesley, G. K., Callstrom, M. R., Schleck, C. D., Harmsen, W. S., ... Welch, T. J. (2010). Incidence of bleeding after 15,181 percutaneous biopsies and the role of aspirin. American Journal of Roentgenology, 194(3), 784-789. https://doi.org/10.2214/AJR.08.2122

Incidence of bleeding after 15,181 percutaneous biopsies and the role of aspirin. / Atwell, Thomas D.; Smith, Ryan L.; Hesley, Gina K.; Callstrom, Matthew R; Schleck, Cathy D.; Harmsen, W. Scott; Charboneau, J. William; Welch, Timothy J.

In: American Journal of Roentgenology, Vol. 194, No. 3, 03.2010, p. 784-789.

Research output: Contribution to journalArticle

Atwell, TD, Smith, RL, Hesley, GK, Callstrom, MR, Schleck, CD, Harmsen, WS, Charboneau, JW & Welch, TJ 2010, 'Incidence of bleeding after 15,181 percutaneous biopsies and the role of aspirin', American Journal of Roentgenology, vol. 194, no. 3, pp. 784-789. https://doi.org/10.2214/AJR.08.2122
Atwell, Thomas D. ; Smith, Ryan L. ; Hesley, Gina K. ; Callstrom, Matthew R ; Schleck, Cathy D. ; Harmsen, W. Scott ; Charboneau, J. William ; Welch, Timothy J. / Incidence of bleeding after 15,181 percutaneous biopsies and the role of aspirin. In: American Journal of Roentgenology. 2010 ; Vol. 194, No. 3. pp. 784-789.
@article{5a015ac37ced4fc1adf1da99eb72d72e,
title = "Incidence of bleeding after 15,181 percutaneous biopsies and the role of aspirin",
abstract = "OBJECTIVE. The objective of our study was to report the incidence of bleeding after imaging-guided percutaneous core biopsy at a single center using a standardized technique. MATERIALS AND METHODS. We performed a retrospective review of percutaneous core biopsies performed at our institution from January 2002 through February 2008. Data were collected at the time of biopsy, and clinical information was obtained 24 hours and 3 months after the biopsy. The specific information that was collected included the results of coagulation studies, aspirin use, the organ biopsied, the size of the biopsy needle, and the number of needle passes. Bleeding complications were defined using the Common Terminology Criteria for Adverse Events (CTCAE, version 3.0) established by the National Cancer Institute. RESULTS. Among the 15,181 percutaneous core biopsies performed during the study period, 70 hemorrhages (0.5{\%}) that were CTCAE grade 3 or greater were identified within 3 months of biopsy. The incidence of bleeding in patients taking aspirin within 10 days before biopsy was 0.6{\%} (18/3,195), which was not statistically different compared with the incidence of bleeding in those not taking aspirin (52/11,986, 0.4{\%}; p = 0.34). The incidence of bleeding after liver biopsy was 0.5{\%}; kidney biopsy, 0.7{\%}; lung biopsy, 0.2{\%}; pancreas biopsy, 1.0{\%}; and other biopsy, 0.2{\%}. There were significant associations between major bleeding and serum platelet count and international normalized ratio (p <0.001), although the association between major bleeding and the size of the biopsy needle was not significant (p = 0.97). CONCLUSION. The overall incidence of major bleeding after imaging-guided percutaneous core needle biopsy is low. Recent aspirin therapy does not appear to significantly increase the risk of such bleeding complications.",
keywords = "Aspirin, Biopsy, Complications, Hemorrhage, Percutaneous biopsy",
author = "Atwell, {Thomas D.} and Smith, {Ryan L.} and Hesley, {Gina K.} and Callstrom, {Matthew R} and Schleck, {Cathy D.} and Harmsen, {W. Scott} and Charboneau, {J. William} and Welch, {Timothy J.}",
year = "2010",
month = "3",
doi = "10.2214/AJR.08.2122",
language = "English (US)",
volume = "194",
pages = "784--789",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "3",

}

TY - JOUR

T1 - Incidence of bleeding after 15,181 percutaneous biopsies and the role of aspirin

AU - Atwell, Thomas D.

AU - Smith, Ryan L.

AU - Hesley, Gina K.

AU - Callstrom, Matthew R

AU - Schleck, Cathy D.

AU - Harmsen, W. Scott

AU - Charboneau, J. William

AU - Welch, Timothy J.

PY - 2010/3

Y1 - 2010/3

N2 - OBJECTIVE. The objective of our study was to report the incidence of bleeding after imaging-guided percutaneous core biopsy at a single center using a standardized technique. MATERIALS AND METHODS. We performed a retrospective review of percutaneous core biopsies performed at our institution from January 2002 through February 2008. Data were collected at the time of biopsy, and clinical information was obtained 24 hours and 3 months after the biopsy. The specific information that was collected included the results of coagulation studies, aspirin use, the organ biopsied, the size of the biopsy needle, and the number of needle passes. Bleeding complications were defined using the Common Terminology Criteria for Adverse Events (CTCAE, version 3.0) established by the National Cancer Institute. RESULTS. Among the 15,181 percutaneous core biopsies performed during the study period, 70 hemorrhages (0.5%) that were CTCAE grade 3 or greater were identified within 3 months of biopsy. The incidence of bleeding in patients taking aspirin within 10 days before biopsy was 0.6% (18/3,195), which was not statistically different compared with the incidence of bleeding in those not taking aspirin (52/11,986, 0.4%; p = 0.34). The incidence of bleeding after liver biopsy was 0.5%; kidney biopsy, 0.7%; lung biopsy, 0.2%; pancreas biopsy, 1.0%; and other biopsy, 0.2%. There were significant associations between major bleeding and serum platelet count and international normalized ratio (p <0.001), although the association between major bleeding and the size of the biopsy needle was not significant (p = 0.97). CONCLUSION. The overall incidence of major bleeding after imaging-guided percutaneous core needle biopsy is low. Recent aspirin therapy does not appear to significantly increase the risk of such bleeding complications.

AB - OBJECTIVE. The objective of our study was to report the incidence of bleeding after imaging-guided percutaneous core biopsy at a single center using a standardized technique. MATERIALS AND METHODS. We performed a retrospective review of percutaneous core biopsies performed at our institution from January 2002 through February 2008. Data were collected at the time of biopsy, and clinical information was obtained 24 hours and 3 months after the biopsy. The specific information that was collected included the results of coagulation studies, aspirin use, the organ biopsied, the size of the biopsy needle, and the number of needle passes. Bleeding complications were defined using the Common Terminology Criteria for Adverse Events (CTCAE, version 3.0) established by the National Cancer Institute. RESULTS. Among the 15,181 percutaneous core biopsies performed during the study period, 70 hemorrhages (0.5%) that were CTCAE grade 3 or greater were identified within 3 months of biopsy. The incidence of bleeding in patients taking aspirin within 10 days before biopsy was 0.6% (18/3,195), which was not statistically different compared with the incidence of bleeding in those not taking aspirin (52/11,986, 0.4%; p = 0.34). The incidence of bleeding after liver biopsy was 0.5%; kidney biopsy, 0.7%; lung biopsy, 0.2%; pancreas biopsy, 1.0%; and other biopsy, 0.2%. There were significant associations between major bleeding and serum platelet count and international normalized ratio (p <0.001), although the association between major bleeding and the size of the biopsy needle was not significant (p = 0.97). CONCLUSION. The overall incidence of major bleeding after imaging-guided percutaneous core needle biopsy is low. Recent aspirin therapy does not appear to significantly increase the risk of such bleeding complications.

KW - Aspirin

KW - Biopsy

KW - Complications

KW - Hemorrhage

KW - Percutaneous biopsy

UR - http://www.scopus.com/inward/record.url?scp=77749298675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749298675&partnerID=8YFLogxK

U2 - 10.2214/AJR.08.2122

DO - 10.2214/AJR.08.2122

M3 - Article

C2 - 20173160

AN - SCOPUS:77749298675

VL - 194

SP - 784

EP - 789

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 3

ER -